Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
PTGX
#1031
Protagonist Therapeutics, Inc
92.080
0
+6.88%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+6.88%
Monatliche Änderung
+11.68%
6 month change
+22.56%
Jahresänderung
+22.56%
Vorheriger Schlusskurs
86.150
0
Open
92.210
0
Bid
Ask
Low
92.080
0
High
92.220
0
Volumen
152
Märkte
Aktien
Gesundheitswesen
PTGX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
43.81 M
48.41 M
51.28 M
58.27 M
61.38 M
63.81 M
—
Valuation ratios
Enterprise value
765.82 M
1.53 B
427 M
1.18 B
2.27 B
5.44 B
15.61 B
Price to earnings ratio
—
—
-4.15
-16.85
9.13
-42.6
197.31
Price to sales ratio
—
—
19.89
22.16
5.78
120.66
173.34
Price to cash flow ratio
—
—
4.89
18.93
13.64
96.28
256.13
Price to book ratio
—
—
2.45
3.95
3.72
9.03
13.23
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.2
0.36
0.51
0.22
0.37
0.19
0.19
Return on equity %
0.24
0.42
0.59
0.23
0.41
0.21
0.2
Return on invested capital %
881.2
2 568.99
5 504.26
6 840.28
655.36
311.93
459.71
Gross margin %
100
100
100
100
100
100
400
Operating margin %
72.17 K
460.01
494.24
156.09
58.2
343.63
2 488.48
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
73.99 K
458.94
479.26
131.59
63.34
282.83
2 099.78
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
7.84
7.74
7.8
16.71
12.48
12.71
59.98
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.08
0.09
0.2
0.79
0.07
0.06
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.03
—
—
—
—
—
—
Long term debt to total equity ratio
0.04
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
2.2
1.24
2.83
0.91
0.93
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
4.84
6.02
6.44
8.92
36.06
Net current asset value per share
—
—
4.96
6.26
9.09
9.09
37.39
Tangible book value per share
—
—
4.4
5.93
10.38
9.67
41.25
Working capital per share
—
—
4.32
5.89
8.36
8.37
34.85
Book value per share
—
—
4.4
5.93
10.38
9.67
41.25
Nachrichten
Protagonist Therapeutics earnings missed by $0.35, revenue fell short of estimates
Citizens raises Protagonist Therapeutics stock price target on drug approvals
Protagonist Therapeutics director Williams sells $1.48 million in shares
Protagonist Therapeutics: Direktor veräußert Aktien im Wert von 1,67 Mio. US-Dollar
Protagonist Therapeutics director sells $1.67 million in shares
Biotech-Ausblick 2026: Truist nennt seine Top-Aktien für die kommenden Jahre
Top Biotech Stocks to Watch in 2026, According to Truist
Protagonist Therapeutics: H.C. Wainwright erhöht Kursziel auf 117 US-Dollar
Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright
Protagonist Stock: Assessing The 2026 Upside For Icotrokinra And Rusfertide (PTGX)
Protagonist Therapeutics: CEO veräußert Aktien im Wert von 4 Mio. US-Dollar
Ali Asif, CFO of protagonist, sells $3.8m in PTGX stock